DE69408541T2 - Kinaserezeptoraktivierungstest - Google Patents

Kinaserezeptoraktivierungstest

Info

Publication number
DE69408541T2
DE69408541T2 DE69408541T DE69408541T DE69408541T2 DE 69408541 T2 DE69408541 T2 DE 69408541T2 DE 69408541 T DE69408541 T DE 69408541T DE 69408541 T DE69408541 T DE 69408541T DE 69408541 T2 DE69408541 T2 DE 69408541T2
Authority
DE
Germany
Prior art keywords
receptor
cells
construct
tyrosine kinase
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69408541T
Other languages
English (en)
Other versions
DE69408541D1 (de
Inventor
Paul Godowski
Melanie Mark
Michael Sadick
Wai Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/170,558 external-priority patent/US6001621A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69408541D1 publication Critical patent/DE69408541D1/de
Publication of DE69408541T2 publication Critical patent/DE69408541T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
DE69408541T 1993-11-23 1994-11-18 Kinaserezeptoraktivierungstest Expired - Lifetime DE69408541T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15756393A 1993-11-23 1993-11-23
US08/170,558 US6001621A (en) 1993-11-23 1993-12-20 Protein tyrosine kinases
US28630594A 1994-08-05 1994-08-05
PCT/US1994/013329 WO1995014930A1 (en) 1993-11-23 1994-11-18 Kinase receptor activation assay

Publications (2)

Publication Number Publication Date
DE69408541D1 DE69408541D1 (de) 1998-03-19
DE69408541T2 true DE69408541T2 (de) 1998-08-06

Family

ID=27388031

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69408541T Expired - Lifetime DE69408541T2 (de) 1993-11-23 1994-11-18 Kinaserezeptoraktivierungstest

Country Status (12)

Country Link
US (3) US6025145A (de)
EP (1) EP0730740B1 (de)
JP (1) JP3442784B2 (de)
AT (1) ATE163231T1 (de)
AU (1) AU698975B2 (de)
CA (1) CA2175892C (de)
DE (1) DE69408541T2 (de)
DK (1) DK0730740T3 (de)
ES (1) ES2116066T3 (de)
GR (1) GR3026430T3 (de)
HK (1) HK1008440A1 (de)
WO (1) WO1995014930A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711341A4 (de) * 1993-07-29 2001-12-19 Cor Therapeutics Inc Rezeptorfunktionstests
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
WO1997025425A1 (en) 1996-01-08 1997-07-17 Genentech, Inc. Wsx receptor and ligands
DK0912734T3 (da) 1996-07-12 2011-02-07 Genentech Inc Kimæriske heteromultimer-adhæsiner
DE69732711T2 (de) 1996-07-12 2006-03-16 Genentech, Inc., South San Francisco Gamma-heregulin
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
FR2776661B1 (fr) * 1998-03-26 2002-04-05 Centre Nat Rech Scient Polypeptide immunoreactif du recepteur trka du ngf et utilisations
US6253441B1 (en) * 1999-04-16 2001-07-03 General Electric Company Fabrication of articles having a coating deposited through a mask
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
EP1229919A2 (de) * 1999-08-06 2002-08-14 Institut Pasteur Verfahren zum beeinflussen der phosphorylierung von eukaryotischen zellen unter verwendung von thiamintriphosphat
US6406869B1 (en) * 1999-10-22 2002-06-18 Pharmacopeia, Inc. Fluorescent capture assay for kinase activity employing anti-phosphotyrosine antibodies as capture and detection agents
WO2001098361A2 (en) * 2000-06-22 2001-12-27 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1436598B1 (de) * 2001-09-10 2013-11-27 Meso Scale Technologies LLC Assay-puffer, diesen enthaltende zusammensetzungen sowie diesen verwendende verfahren
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
AU2003228225B2 (en) * 2002-03-01 2010-05-13 Roger Williams Hospital SHC protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
ES2376165T3 (es) 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
US20060147450A1 (en) * 2002-10-04 2006-07-06 Shelton David L Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
RU2338555C2 (ru) 2002-10-08 2008-11-20 Ринат Ньюросайенс Корп. Способы лечения послеоперационной боли введением антагониста фактора роста нервов и композиции, содержащие фактор роста нервов
AU2003304238A1 (en) * 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US20050089521A1 (en) * 2002-12-23 2005-04-28 Shelton David L. Methods for treating taxol-induced sensory neuropathy
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
SI1575517T1 (sl) * 2002-12-24 2012-06-29 Rinat Neuroscience Corp Protitelesa proti ĺ˝iväśnemu rastnemu dejavniku in metode njihove uporabe
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PL379983A1 (pl) 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
ES2263862T3 (es) * 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GEP20094629B (en) 2003-03-19 2009-03-10 Biogen Idec Inc Nogo receptor binding protein
EP1620127A4 (de) * 2003-03-20 2007-04-04 Rinat Neuroscience Corp Verfahren zur behandlung von taxol-induzierten darmstörungen
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
JP5301152B2 (ja) * 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
WO2006002437A2 (en) 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
AU2005287404B2 (en) 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1662258A1 (de) * 2004-11-25 2006-05-31 Sirenade Pharmaceuticals AG In Vitro Testverfahren zum Nachweis von substratfreier Proteinkinase-Aktivität
KR20190110637A (ko) 2005-01-21 2019-09-30 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
SI1850874T1 (sl) 2005-02-23 2014-01-31 Genentech, Inc. Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
WO2006098804A2 (en) * 2005-03-11 2006-09-21 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
EP2238986A3 (de) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35-Antikörper und Verwendungen dafür
ATE521893T1 (de) * 2005-11-11 2011-09-15 Roger Williams Hospital P66-shc als prädiktiver marker bei der krebsbehandlung
CA2631181A1 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
AU2008311251B9 (en) * 2007-10-11 2014-04-17 Biogen Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and TrkB agonists
US8097434B2 (en) 2007-10-19 2012-01-17 Becton, Dickinson And Company Methods for the detection of beta-lactamases
AU2008317329B2 (en) * 2007-10-24 2014-10-02 Biomarker Strategies, Llc Improved methods and devices for cellular analysis
JP5564431B2 (ja) 2007-10-29 2014-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼアラレノンアナログ化合物ががんを処置する能力を予測する方法
US20110123553A1 (en) * 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
PT2250279E (pt) 2008-02-08 2016-06-03 Medimmune Llc Anticorpos anti-ifnár1 com afinidade reduzida para o ligando fc
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
US20100022916A1 (en) 2008-07-24 2010-01-28 Javanbakhsh Esfandiari Method and Apparatus for Collecting and Preparing Biological Samples for Testing
CA2734895C (en) * 2008-08-18 2014-06-17 Discoverx Corporation Receptor tyrosine kinase assays
BRPI0917888A2 (pt) 2008-09-19 2014-02-25 Pfizer Formulação de anticorpo líquida estável
US9834807B2 (en) * 2008-10-20 2017-12-05 Becton, Dickinson And Company Compositions for the detection of intracellular bacterial targets and other intracellular micororganism targets
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
KR101961254B1 (ko) 2009-10-26 2019-03-22 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CN106062560A (zh) 2014-03-31 2016-10-26 默克专利股份公司 使用特异性抗体检测蛋白质修饰的方法
CN111077309B (zh) 2014-04-02 2023-11-17 生化诊断系统公司 利用俘获缀合物的免疫测定
US20160116466A1 (en) 2014-10-27 2016-04-28 Chembio Diagnostic Systems, Inc. Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses
EP3242893A1 (de) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1-antagonisten und verwendungen zur behandlung von demyelinisierungserkrankungen
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3311889A1 (de) * 1983-03-31 1984-10-11 Byk-Mallinckrodt Chemische Produkte Gmbh, 6057 Dietzenbach Verfahren zur irreversiblen bindung von protein an polystyroloberflaechen unter erhaltung der biologischen aktivitaet, so erhaltene polystyroloberflaechen und ihre verwendung
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
EP0624192A1 (de) * 1992-01-22 1994-11-17 New England Deaconess Hospital Neue Protein Tyrosinkinasen
AU4281393A (en) * 1992-04-10 1993-11-18 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
WO1994019463A2 (en) * 1993-02-16 1994-09-01 Auckland Uniservices Limited Developmental tyrosine kinases and their ligands

Also Published As

Publication number Publication date
AU1210895A (en) 1995-06-13
WO1995014930A1 (en) 1995-06-01
JP3442784B2 (ja) 2003-09-02
US6025145A (en) 2000-02-15
JPH09505889A (ja) 1997-06-10
HK1008440A1 (en) 1999-05-07
ES2116066T3 (es) 1998-07-01
EP0730740B1 (de) 1998-02-11
US5891650A (en) 1999-04-06
AU698975B2 (en) 1998-11-12
EP0730740A1 (de) 1996-09-11
ATE163231T1 (de) 1998-02-15
CA2175892A1 (en) 1995-06-01
GR3026430T3 (en) 1998-06-30
DK0730740T3 (da) 1998-09-28
DE69408541D1 (de) 1998-03-19
US5914237A (en) 1999-06-22
CA2175892C (en) 2000-03-07

Similar Documents

Publication Publication Date Title
DE69408541T2 (de) Kinaserezeptoraktivierungstest
Wilce et al. Physicochemical basis of amino acid hydrophobicity scales: evaluation of four new scales of amino acid hydrophobicity coefficients derived from RP-HPLC of peptides
IL101233A (en) Receptor-based screening and identifying methods for amylin agonists and antagonists
ATE217344T1 (de) Antigen bindende peptide (abtides) aus peptidbibliotheken
DE69334100D1 (de) Elk ligand, ein cytokin
TR200002257T2 (tr) Nükleer reseptör ligandları ve ligand bağlanma domainleri.
CA2423979A1 (en) Method for quantifying phosphokinase activity on proteins
EP0873998A3 (de) Rezeptor-Protein und seine Verwendung
Morris et al. Cellular enzyme-linked immunospecific assay (CELISA). I a new micromethod that detects antibodies to cell-surface antigens
US4703016A (en) Silver stain for rapid, quantitative detection of polypeptides and nucleic acids
CA2279881A1 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
CN101896816A (zh) 用于检测分析物的方法
CA2203246A1 (en) Alk-7 (activin like kinase), a serine threonine kinase receptor
Chin et al. The use of tributylphosphine and 4-(aminosulfonyl)-7-fluoro-2, 1, 3-benzoxadiazole in the study of protein sulfhydryls and disulfides
Rehfeld et al. Residue-specific radioimmunoanalysis: a novel analytical tool. Application to the C-terminus of CCK/gastrin peptides
Moss et al. Solubility and posttranslational regulation of GP130/F11--a neuronal GPI-linked cell adhesion molecule enriched in the neuronal membrane skeleton.
CA2294969A1 (en) Surfaces coated with streptavindin/avidin
JP2008029320A5 (de)
US6156529A (en) Method for specifically marking a protein
AU2434400A (en) Method for the cellular high-throughput-detection of nuclear receptor ligand interactions
DE59914900D1 (de) Methode zur zellulären high-throughput-detektion von rezeptor-liganden-interaktionen
Harper et al. Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex
AU8857991A (en) Polypeptides having human dopaminergic receptor activity, nucleic acids coding for said polypeptides and uses thereof for screening active substances on said polypeptides
Diehl-Seifert et al. Directed migration of cells from the sponge Geodia cydonium

Legal Events

Date Code Title Description
8364 No opposition during term of opposition